---
title: 'Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin
  for chronic kidney disease: a randomised, controlled, phase 2 trial'
date: '2023-12-18'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38109916/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231219170639&v=2.18.0
source: heidelberg[Affiliation]
description: 'BACKGROUND: Excess aldosterone accelerates chronic kidney disease progression.
  This phase 2 clinical trial assessed BI 690517, an aldosterone synthase inhibitor,
  for efficacy, safety, and dose ...'
disable_comments: true
---
BACKGROUND: Excess aldosterone accelerates chronic kidney disease progression. This phase 2 clinical trial assessed BI 690517, an aldosterone synthase inhibitor, for efficacy, safety, and dose ...